CAJ | 학술논문

目的探讨套细胞淋巴瘤(MCL)患者的临床特点、不同治疗方案的疗效及影响预后的主要因素.方法回顾性分析2002年1月至2011年12月收治的47例MCL患者资料,并结合临床特征和治疗方案进行相关预后因素分析.结果 47例患者中位发病年龄58岁,男女比例3.3∶1,Ann Arbor分期Ⅲ～Ⅳ期为主(42例,占89.4％).骨髓累及者13例(27.7％),淋巴细胞绝对值升高者6例(12.8％),乳酸脱氢酶(LDH)升高者18例(38.3％)；β2-微球蛋白(β2-MG)升高者28例(59.6％).年龄＞60岁、骨髓受累、LDH升高及治疗方案中未加用利妥昔单抗为预后不良因素.利妥昔单抗联合化疗方案有效率及完全缓解率分别为91.4％和48.6％,均优于CHOP方案(41.7％和16.7％),且在无进展生存率及总生存率方面都体现出明显优势.结论 MCL患者多为老年男性,易伴骨髓受累,预后差.利妥昔单抗联合化疗可显著提高疗效及改善生存.
목적 탐토투세포림파류(MCL)환자적림상특점、불동치료방안적료효급영향예후적주요인소.방법 회고성분석2002년1월지2011년12월수치적47례MCL환자자료,병결합림상특정화치료방안진행상관예후인소분석.결과 47례환자중위발병년령58세,남녀비례3.3∶1,Ann Arbor분기Ⅲ～Ⅳ기위주(42례,점89.4％).골수루급자13례(27.7％),림파세포절대치승고자6례(12.8％),유산탈경매(LDH)승고자18례(38.3％)；β2-미구단백(β2-MG)승고자28례(59.6％).년령＞60세、골수수루、LDH승고급치료방안중미가용리타석단항위예후불량인소.리타석단항연합화료방안유효솔급완전완해솔분별위91.4％화48.6％,균우우CHOP방안(41.7％화16.7％),차재무진전생존솔급총생존솔방면도체현출명현우세.결론 MCL환자다위노년남성,역반골수수루,예후차.리타석단항연합화료가현저제고료효급개선생존.
Objective To study the clinical features,therapeutic effects,survival time and prognostic factors of patents with mantle cell lymphoma (MCL).Methods Clinical data of 47 MCL patients admitted from January 2002 to December 2011 were retrospectively analyzed.Results Of all patients,median age was 58 year-old and male to female ratio was 3.3∶ 1.Forty-two cases (89.4％) were in Ann Arbor stage Ⅲ-Ⅳ,13 cases (27.7％) with bone marrow involvement,6 cases (12.8％) with lymphocytosis,18 cases (38.3％) with elevated LDH,and 28 cases (59.6％) with elevated β2-MG.Age,bone marrow involvement,increased LDH level and treatment without rituximab were poor prognostic factors.The efficiency and complete remission rate of rituximab combined with chemotherapy were 91.4％ and 48.6％,which were superior to those of CHOP regimen (41.7％ and 16.7％).As compared to CHOP regimen,rituximab combined with chemotherapy induced longer progression-free survival and overall survival.Conclusion Most patients with MCL were older adults with a male predominance and usually had bone marrow involvement and poor prognosis.Rituximab combined with chemotherapy could significantly improve patient outcome.